Tcr2 Therapeutics Valuation
| TCRRDelisted Stock | USD 1.48 0.00 0.00% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Tcr2 Therapeutics has a current Real Value of $1.35 per share. The regular price of the company is $1.48. Our model measures the value of Tcr2 Therapeutics from inspecting the company fundamentals such as Shares Outstanding of 39.26 M, shares owned by institutions of 54.31 %, and Return On Equity of -0.91 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Tcr2 Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Tcr2 Therapeutics is based on 3 months time horizon. Increasing Tcr2 Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Tcr2 stock is determined by what a typical buyer is willing to pay for full or partial control of Tcr2 Therapeutics. Since Tcr2 Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tcr2 Stock. However, Tcr2 Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.48 | Real 1.35 | Hype 1.48 | Naive 1.35 |
The intrinsic value of Tcr2 Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Tcr2 Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Tcr2 Therapeutics helps investors to forecast how Tcr2 stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tcr2 Therapeutics more accurately as focusing exclusively on Tcr2 Therapeutics' fundamentals will not take into account other important factors: Tcr2 Therapeutics Total Value Analysis
Tcr2 Therapeutics is at this time projected to have valuation of (73.69 M) with market capitalization of 58.11 M, debt of 58.23 M, and cash on hands of 175.99 M. The negative valuation of Tcr2 Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Tcr2 Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(73.69 M) | 58.11 M | 58.23 M | 175.99 M |
Tcr2 Therapeutics Asset Utilization
One of the ways to look at asset utilization of Tcr2 is to check how much profit was generated for every dollar of assets it reports. Tcr2 Therapeutics has a negative utilization of assets of -0.35 %, losing $0.003473 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Tcr2 Therapeutics shows how discouraging it operates for each dollar spent on its assets.Tcr2 Therapeutics Ownership Allocation
Tcr2 Therapeutics shows a total of 39.26 Million outstanding shares. Over half of Tcr2 Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Tcr2 Therapeutics Profitability Analysis
Net Loss for the year was (151.82 M) with profit before overhead, payroll, taxes, and interest of 0.About Tcr2 Therapeutics Valuation
The delisted stock valuation mechanism determines Tcr2 Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Tcr2 Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Tcr2 Therapeutics. We calculate exposure to Tcr2 Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tcr2 Therapeutics's related companies.TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor therapies for patients suffering from cancer. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Tcr2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people.
Tcr2 Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Tcr2 Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 38.6 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |